Zepbound for Sleep Apnea: The May 2026 Playbook

A reader emailed last week with the cleanest version of the question I've gotten in months. "I've worn a CPAP for nine years. My pulmonologist mentioned Zepbound. My 2017 sleep study said AHI 38. Does any of that paperwork still count?" One inbox, the whole May 2026 conversation.

On December 20, 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever cleared for OSA. Not a device, not a positional therapy. A once-weekly shot. Sixteen months later, on July 1, 2026, Medicare Part D opens the GLP-1 Bridge: Zepbound at a $50/mo co-pay for beneficiaries who clear the SURMOUNT-OSA bar. The approval told clinicians they could prescribe it. The coverage flip is what decides whose prescriptions actually get filled.

The rest of this piece walks through the trial numbers, what the label really covers, what Zepbound costs this month versus in July, what to bring to your sleep doc, and where the rest of the world sits — because the US is the only market with an OSA indication today, and the questions outside it stack up differently.

The number that changed sleep medicine

SURMOUNT-OSA published in the New England Journal of Medicine on June 21, 2024. Two parallel Phase 3 trials, 52 weeks, max tolerated tirzepatide up to 15 mg subcutaneous once weekly, in adults with moderate-to-severe OSA and BMI of 30 or higher.

A 25-to-29 event-per-hour AHI drop is not a tweak. Baseline AHI of 51.5 is severe by every guideline — anything above 30 events/h crosses the line. At week 52, 51.5% of Study 1 participants and 43.2% of Study 2 participants hit OSA disease resolution, defined as AHI under 5, or AHI 5 to 14 without daytime symptoms. Half the cohort, twelve months, one weekly injection.

The result pushed the FDA's December 20, 2024 approval letter through faster than most label expansions. The trial sits at NEJM; the FDA announcement is here.

Half the no-PAP arm reached disease resolution. Most sleep clinics underweighted that line at first, because nobody trained in 2018 expected a drug to do this. The curriculum has caught up by 2026.

What the FDA approved — and what it didn't

Specificity matters, because insurance reads the label literally.

The Zepbound OSA indication covers adults with moderate-to-severe obstructive sleep apnea AND obesity (BMI ≥30). Both conditions, same patient, documented. The label does not cover mild OSA. It does not cover OSA in patients with BMI 27 to 29, even with a comorbidity — the obesity-with-comorbidity gate still applies to the obesity indication but not the OSA one. Central sleep apnea, mixed apnea, and pediatric OSA are all out of scope.

Translated for the pharmacy counter:

• A sleep study — home sleep apnea test (HSAT) or attended polysomnography — documenting AHI ≥15.
• A current BMI ≥30, charted by your prescriber.
• The prescription written under Zepbound, not Mounjaro. Same molecule, different label, different insurance pathway.
• Standard tirzepatide titration: 2.5 mg weekly for four weeks, then step up by 2.5 mg every four weeks as tolerated, to a maintenance dose of 5 to 15 mg.

If you're already on Zepbound for obesity and your sleep study confirms moderate-to-severe OSA, you don't necessarily swap drug or dose. You change what the chart says the drug is treating, and that can change how it gets covered. More on that below.

The CPAP question, asked plainly

This is the question that lights up r/SleepApnea every week since the approval. Do I still need my CPAP?

The honest answer is: probably yes, and definitely don't decide that on your own. Even in Study 2 — where every participant was on PAP at baseline and lost 20.1% of body weight on tirzepatide — disease resolution at 52 weeks was 43.2%. Roughly six in ten participants still had clinically meaningful OSA at the end of a year, on a drug that worked.

The right pattern in May 2026 looks more like this. Start tirzepatide. Stay on CPAP. After about six months of weight loss and stable maintenance, repeat the sleep study. If the AHI drops below the threshold your sleep doc considers safe to discontinue PAP, then you have a real conversation about a CPAP holiday or weaning. Not before. The cardiovascular cost of untreated severe OSA — atrial fibrillation, stroke risk, daytime crashes behind the wheel — is the kind of thing that doesn't care about your weight chart until it suddenly does.

One more note, for partners. CPAP is also the reason a lot of people still share a bed. If you're hoping to stop wearing it, the data right now says wait, then test, then decide.

What Zepbound for OSA actually costs in May 2026

Here's the table everyone's looking for. Zepbound as billed at the pharmacy this month, versus what's about to change.

Two things worth stating out loud. The Hims line is on this table because readers ask about it constantly. The answer is that Hims' weight-loss tier runs on semaglutide through the March 2026 Novo deal, not tirzepatide, and there's no DTC channel selling Zepbound for OSA at $149/mo today. If you want tirzepatide for OSA, you go through a prescriber and one of the rows above. The full backstory on the Hims-Novo $149 lane is in our coverage of the March 2026 D2C reset.

The other thing: Medicare at $50/mo on July 1 is the cheapest legal path that exists for OSA-qualifying beneficiaries. If you're a Medicare enrollee who's been priced out of GLP-1s for years, the calendar matters. CMS announced the GLP-1 Bridge framework in late 2025, covering Wegovy under SELECT cardiovascular criteria and Zepbound under SURMOUNT-OSA criteria — both at the $50/mo Part D co-pay tier for qualifying beneficiaries.

How insurance reads "Zepbound for OSA" vs "Zepbound for obesity"

Same drug. Different chart code. Different prior authorization form. Sometimes a different formulary tier. This is the part that surprises people the most.

Before December 2024, every Zepbound prior auth ran through the obesity indication. The PA template asked for BMI documentation, prior weight-loss attempts, sometimes a six-month diet-and-exercise log, and almost always a list of comorbidities. Plenty of commercial plans just excluded anti-obesity medications, full stop, regardless of what you submitted.

Post-OSA approval, a parallel pathway opened. If your AHI is ≥15 documented, your BMI is ≥30, and your plan covers Zepbound under the OSA indication, the PA form is shorter and the formulary placement may land softer — because OSA is a covered medical condition under almost every commercial and Medicare plan, in a way that obesity historically wasn't.

The practical move for a patient who qualifies on both fronts: ask your prescriber to file under the OSA indication if your sleep study supports it. The drug, dose, and titration don't change. The paperwork does. Some plans that deny obesity Zepbound will approve OSA Zepbound on the same day for the same patient.

This is where Mounjaro vs Zepbound trips people up. Same molecule (tirzepatide), but Mounjaro is labeled for type 2 diabetes only, and Zepbound is labeled for obesity and OSA. If your insurance denies Zepbound but your prescriber writes Mounjaro because you also have T2D, you get the same molecule through a different door — but you can't use a Zepbound savings card on a Mounjaro fill, and the OSA paperwork doesn't apply. Our Mounjaro titration schedule guide walks through the dose ladder if you land on either label.

The Medicare GLP-1 Bridge — what July 1 actually does

CMS opens the GLP-1 Bridge program on July 1, 2026. Two tracks:

1. Wegovy under the SELECT cardiovascular criteria — adults with established cardiovascular disease and overweight or obesity.
2. Zepbound under the SURMOUNT-OSA criteria — adults with moderate-to-severe OSA and obesity.

Both at $50/mo through Part D for qualifying beneficiaries. Same co-pay tier, both drugs.

Picture a 67-year-old on Medicare with severe OSA, BMI 34, who's been paying $1,086 cash or $349 to $499 through LillyDirect for the past year. Starting July 1, monthly out-of-pocket likely drops by 85% to 95%. Clinical eligibility is gated by your existing sleep study — or a new one, if the last one is too old or doesn't meet plan requirements — plus BMI documentation.

A few things that aren't automatic. Your specific Part D plan has to adopt the bridge formulary placement. Most are expected to, but timing varies. Your sleep study has to meet the plan's documentation standard, which usually means within the past 12 to 24 months and conducted in an accredited lab or through an approved HSAT. SURMOUNT-OSA criteria get interpreted at the plan level — most are aligning on the AHI ≥15 + BMI ≥30 threshold the trial used, but the prior auth form will spell out what your plan accepts. CMS posted the framework details at its GLP-1 Bridge announcement page (search "GLP-1 Bridge 2026"), and individual plan formularies are landing through Q2.

Medicare didn't cover anti-obesity medications for almost 20 years. The OSA indication is the workaround that made Zepbound a covered drug for the first time, because OSA is a cardiopulmonary condition, not a weight-loss request.

If you're 64 and turning 65 between now and the end of 2026, raise this at your Medicare enrollment appointment. If you're already on Medicare, ask your plan whether they're filing Zepbound under the bridge formulary.

How the rest of the world is approaching tirzepatide for OSA

The US sits alone on the OSA indication right now. The global picture as of May 2026:

A few things from that grid. Outside the US, the same molecule almost always sits under one brand (Mounjaro), not split into Zepbound and Mounjaro. So when EMA or PMDA eventually adds an OSA indication, it lands on the existing Mounjaro label rather than launching a new brand the way Zepbound did. EMA's CHMP opinion is the next domino. Once that lands mid-2026, individual EU national payers will decide reimbursement on their own timelines.

Japan and Korea are watching SURMOUNT-OSA closely but moving conservatively. PMDA's standard practice is to require Japan-resident bridging data before a label expansion, and that work isn't finished. Korea's MFDS is earlier still on OSA. For readers in Asia who want tirzepatide for sleep apnea right now, the practical path is the existing obesity indication where one exists, with OSA documented as a comorbidity rather than the primary indication. That doesn't always change pricing. It does change how the chart reads.

Australia and the UK both look like markets that will move once EMA does. Neither has a domestic OSA filing in public view as of May 2026.

What to ask at your next sleep medicine visit

A short list, written for the actual conversation.

• "What's my most recent AHI on the chart, and is the documentation recent enough to support a Zepbound prior authorization?" If your last sleep study is from 2018, you may need a repeat HSAT or polysomnography before the PA clears.
• "Do you write Zepbound for OSA in your practice, or do you refer to obesity medicine for the prescription?" Some sleep docs prescribe. Many refer. Knowing ahead of time saves a month.
• "If I start Zepbound, when do you want to repeat the sleep study to reassess my CPAP need?" Six months is the common answer right now. Get it on the calendar.
• "How do you handle dose escalation if I get GI side effects in months one through three?" Standard tirzepatide titration is 2.5 mg for four weeks, then step up by 2.5 mg every four weeks. Some clinicians stretch the early steps if nausea is severe.
• "What's your plan if my insurance denies the OSA indication PA?" Appeal templates with SURMOUNT-OSA citations exist. Ask whether the practice's billing team has one.
• "Am I a candidate for the Medicare GLP-1 Bridge in July, and if so, what does my Part D plan need from me before then?" Worth raising even if you're not Medicare-eligible yet — your spouse or parent might be.

If your sleep doc seems unfamiliar with the OSA indication, that's not a red flag. It's a calendar fact. The label is 16 months old as of May 2026, and most sleep medicine training programs are still updating their pharmacology modules. Bringing a printed copy of the SURMOUNT-OSA NEJM abstract to the visit is a reasonable thing to do.

Before your first fill — or your next refill

A checklist that prevents the most common headaches in the first 90 days.

1. Confirm the indication on the prescription. OSA-indicated Zepbound runs through a different PA path than obesity-indicated Zepbound. Make sure your prescriber checked the right box.
2. Get your sleep study and BMI in the chart in writing. Pharmacy and PA reviewers want to see the AHI number and a current BMI. "Severe OSA" without a number gets kicked back.
3. Check your savings card eligibility before your first fill. Commercial savings card runs $25/mo for eligible patients; uninsured coupon runs $550. Lilly's portal verifies in real time. Don't show up at the pharmacy assuming the card will activate at the counter.
4. Pen vs vial — make sure the pharmacy stocks what you're prescribed. LillyDirect self-pay at $349 to $499 is vial-only, for the 2.5 mg and 5 mg starter doses. If you're prescribed a pen autoinjector and your plan doesn't cover it, you may need to switch to vials and learn the syringe draw, or pay full retail.
5. Plan your titration calendar. Four weeks at 2.5 mg, then 5 mg, then 7.5 mg, then 10 mg. Side effects cluster in week one of each step. One small thing that helps: take the shot the same day each week, ideally a day where you can be home for the evening.
6. Don't stop CPAP without your sleep doc's sign-off. Worth saying twice. The drug works on weight, and weight works on AHI, but the timeline is months, not weeks. Your CPAP is doing real cardiovascular work in the meantime.
7. Set a six-month repeat sleep study reminder. Whether it's a follow-up HSAT or in-lab PSG depends on your insurance. Get it scheduled at month four so it lands at month six.

If you're switching from Mounjaro to Zepbound to chase the OSA indication, the molecule and dose are the same, and the savings card does not transfer. A side-by-side of the broader GLP-1 landscape is in our Wegovy vs Mounjaro comparison if you're still mapping out which drug to land on.

Three dates to watch

July 1, 2026. Medicare GLP-1 Bridge opens. The first quarter of fills will tell us how many of the 67 million Part D enrollees move through the SURMOUNT-OSA gate. Analyst estimates cluster at 1 to 3 million qualifying for the Zepbound track in the first 18 months. The real number depends on how aggressively plans interpret AHI documentation requirements.

Mid-2026. EMA CHMP opinion on tirzepatide for OSA. If positive, expect EU national payer decisions to roll through 2027. Watch Germany and the Nordics first — they tend to move fastest on cardiopulmonary indications.

Q4 2026 earnings. Lilly will break out Zepbound OSA-indication volumes for the first time. That's the data point investors and patients will both watch. It'll show whether the OSA pathway is pulling new patients in, or just relabeling existing obesity patients.

The bigger picture: tirzepatide for sleep apnea is the first time a weight-loss drug got approved primarily for a cardiopulmonary outcome, with weight loss treated almost as the mechanism rather than the goal. That framing is already pulling other GLP-1 trials in the same direction. The SUMMIT heart-failure data on tirzepatide hit a similar nerve last year. SURMOUNT-MMO's mortality endpoint reads next.

For roughly 24 million US adults with moderate-to-severe OSA — and for the 425 million worldwide that Benjafield's 2019 Lancet Respiratory Medicine modeling estimated, give or take a margin nobody in epidemiology has tightened since — the question stops being "can a drug do this" and starts being "will my plan let me have it." On July 1, for a meaningful slice of US Medicare beneficiaries, the answer flips to yes. The rest of the world will read what happens next as either the proof or the warning.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app